The antitumor effects of entinostat in ovarian cancer require adaptive immunity-Reference-Cited by-同舟云学术

The antitumor effects of entinostat in ovarian cancer require adaptive immunity

Published:2018-11-13 Issue:24 Volume:124 Page:4657-4666
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Smith Haller J.¹,McCaw Tyler R.²,Londono Angelina I.³,Katre Ashwini A.³,Meza‐Perez Selene²,Yang Eddy S.³,Forero Andres⁴,Buchsbaum Donald J.³,Randall Troy D.²,Straughn, Jr J. Michael¹,Norian Lyse A.⁵,Arend Rebecca C.¹

Affiliation:

1. Division of Gynecologic OncologyUniversity of Alabama at Birmingham Birmingham Alabama

2. Division of Clinical Immunology and RheumatologyUniversity of Alabama at Birmingham Birmingham Alabama

3. Department of Radiation OncologyUniversity of Alabama at Birmingham Birmingham Alabama

4. Division of Hematology and OncologyUniversity of Alabama at Birmingham Birmingham Alabama

5. Department of Nutrition SciencesUniversity of Alabama at Birmingham Birmingham Alabama

Funder

Foundation for Women's Cancer

University of Alabama at Birmingham

Center for Clinical and Translational Science, University of Illinois at Chicago

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.31761

Reference41 articles.

1. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

2. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

3. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

4. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

5. Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MS275 induces tumor immunosuppression by up-regulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer;2024-03-22

2. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors;Cancers;2023-12-23

3. Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy;Frontiers in Immunology;2023-09-06

4. Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer;Biochemical Pharmacology;2023-09

5. “DEPHENCE” system—a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer—a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies;Frontiers in Oncology;2023-06-28